℞ Prescription injectable Antibiotics
CS-TAZ 1.125
Piperacillin & Tazobactam For Injection I.P.
A Powerful Combination for Complex Infections
1.125 gm Lyophilized powder for injection
- Broad Spectrum Antibacterial Coverage
- Enhanced Efficacy with Beta-Lactamase Inhibitor
- Rapid Clinical Response
- Ideal for Hospital & ICU Settings
- Effective Against Resistant Organisms
- Clinically Proven
Specifications
| Composition | Each vial contains: Piperacillin Sodium I.P. (as sterile) 1.0 gm; Tazobactam Sodium I.P. (as sterile) 0.125 gm |
|---|---|
| Strength | 1.125 gm |
| Dosage form | Lyophilized powder for injection |
| Pack size | 1 Vial (1.125 gm) with Sterile Water for Injection (as per pack) |
| Route | Intravenous (I.V.) use only |
| Storage | Store below 25°C. Protect from moisture and light. |
Indications
- Complicated intra-abdominal infections (e.g., peritonitis, appendicitis)
- Complicated urinary tract infections (cUTI)
- Hospital-acquired & ventilator-associated pneumonia (HAP/VAP)
- Complicated skin and soft tissue infections (including diabetic foot infections)
- Intra-gynaecological and post-operative infections
- Septicemia and bloodstream infections
- Infections in immunocompromised patients
- Empirical therapy in severe polymicrobial infections
Mechanism of action
Piperacillin is a broad-spectrum ureidopenicillin that inhibits bacterial cell wall synthesis. Tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamase producing organisms, thereby extending its spectrum of activity against resistant bacteria.
Dosage and administration
- Dose and duration as directed by the Physician.
- For intravenous use only.
- Reconstitute with sterile water for injection as per protocol.
- Administer by slow I.V. infusion (as per clinical condition).
- Use under medical supervision.
Safety information
- For single use only.
- Use under strict medical supervision.
- Use with caution in patients with renal impairment.
- Hypersensitivity to penicillins, cephalosporins or β-lactamase inhibitors should be considered.
- Refer to full prescribing information.
For use by registered medical practitioners, hospitals and laboratories only. Refer to the full prescribing information before use.
